CL2023002148A1 - Anticuerpos anti- pdgf-b y métodos de su uso para tratar hipertensión arterial pulmonar (pah) - Google Patents

Anticuerpos anti- pdgf-b y métodos de su uso para tratar hipertensión arterial pulmonar (pah)

Info

Publication number
CL2023002148A1
CL2023002148A1 CL2023002148A CL2023002148A CL2023002148A1 CL 2023002148 A1 CL2023002148 A1 CL 2023002148A1 CL 2023002148 A CL2023002148 A CL 2023002148A CL 2023002148 A CL2023002148 A CL 2023002148A CL 2023002148 A1 CL2023002148 A1 CL 2023002148A1
Authority
CL
Chile
Prior art keywords
antibodies
pah
pdgf
methods
arterial hypertension
Prior art date
Application number
CL2023002148A
Other languages
English (en)
Spanish (es)
Inventor
Yinglin Gao
Scott Macdonnell
Bharathi Sundaram
Jee Kim
Priore Isabella Del
Jake Megna
qin Ruan
Lori C Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023002148A1 publication Critical patent/CL2023002148A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023002148A 2021-01-25 2023-07-21 Anticuerpos anti- pdgf-b y métodos de su uso para tratar hipertensión arterial pulmonar (pah) CL2023002148A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25

Publications (1)

Publication Number Publication Date
CL2023002148A1 true CL2023002148A1 (es) 2024-04-12

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002148A CL2023002148A1 (es) 2021-01-25 2023-07-21 Anticuerpos anti- pdgf-b y métodos de su uso para tratar hipertensión arterial pulmonar (pah)

Country Status (13)

Country Link
US (2) US12030935B2 (https=)
EP (1) EP4281475A1 (https=)
JP (1) JP2024505195A (https=)
KR (1) KR20230135627A (https=)
CN (1) CN116964088A (https=)
AU (1) AU2022210475A1 (https=)
BR (1) BR112023014337A8 (https=)
CA (1) CA3205846A1 (https=)
CL (1) CL2023002148A1 (https=)
CO (1) CO2023010900A2 (https=)
IL (1) IL304505A (https=)
MX (1) MX2023008691A (https=)
WO (1) WO2022159875A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120028552B (zh) * 2025-02-28 2025-08-19 上海交通大学医学院附属上海儿童医学中心 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HK1216428A1 (zh) * 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法

Also Published As

Publication number Publication date
US20220242943A1 (en) 2022-08-04
KR20230135627A (ko) 2023-09-25
AU2022210475A1 (en) 2023-08-10
CO2023010900A2 (es) 2023-08-28
US20240425574A1 (en) 2024-12-26
BR112023014337A8 (pt) 2024-03-05
CA3205846A1 (en) 2022-07-28
MX2023008691A (es) 2023-08-01
EP4281475A1 (en) 2023-11-29
US12030935B2 (en) 2024-07-09
CN116964088A (zh) 2023-10-27
BR112023014337A2 (pt) 2023-09-26
JP2024505195A (ja) 2024-02-05
IL304505A (en) 2023-09-01
WO2022159875A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
UA130334C2 (uk) Способи лікування астми за допомогою антитіла до tslp
DOP2018000272A (es) Conjugados de anticuerpo anti-egfr y fármaco
MX2021013713A (es) Celulas pluripotentes modificadas.
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
CL2023003432A1 (es) Fragmento de union fab de igg1 del anticuerpo anti-tslp
CO2023010900A2 (es) Anticuerpos anti- pdgf-b y métodos de su uso para tratar la hipertensión arterial pulmonar (pah)
CR20220244A (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
BR112021019120A2 (pt) Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
MX2023003304A (es) Complejo de union de egfr y metodo de fabricacion y uso del mismo.
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
EA201990613A1 (ru) Антитела против гремлина-1 (grem1) и способы их применения для лечения легочной артериальной гипертензии
EP4650367A3 (en) Anti-stem cell factor antibodies and methods of use thereof
UY38534A (es) Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza huma
AR069885A1 (es) Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional
ES2401268R1 (es) Capsicum portainjerto
MX2022002371A (es) Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.
MX2024015079A (es) Moduladores de rxfp1 para el tratamiento de la hipertension resistente o la insuficiencia cardiaca con hipertension pulmonar
MX2022010915A (es) Anticuerpos anti-cd19, metodos de uso y fabricacion de los mismos.
AR114380A1 (es) VARIANTES DE Ab, ENSAYO, MÉTODO Y TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
AR120373A1 (es) Moléculas de fusión siglec-9 ecd y sus métodos de uso
Schia Erratum to: Bureaucratic Entrepreneurship: Liberian Ministries, International Consultants, and Making Connections
PL415391A1 (pl) Sekwencja białkowa, zwłaszcza stanowiąca fragment przeciwciała, oddziałującego specyficznie z ludzkim i mysim czynnikiem wzrostu śródbłonka naczyniowego C oraz jej zastosowanie